<code id='E9C9113119'></code><style id='E9C9113119'></style>
      • <acronym id='E9C9113119'></acronym>
      <center id='E9C9113119'><center id='E9C9113119'><tfoot id='E9C9113119'></tfoot></center><abbr id='E9C9113119'><dir id='E9C9113119'><tfoot id='E9C9113119'></tfoot><noframes id='E9C9113119'>
      • <optgroup id='E9C9113119'><strike id='E9C9113119'><sup id='E9C9113119'></sup></strike><code id='E9C9113119'></code></optgroup>
        5. <b id='E9C9113119'><label id='E9C9113119'><select id='E9C9113119'><dt id='E9C9113119'><span id='E9C9113119'></span></dt></select></label></b><u id='E9C9113119'></u>
          <i id='E9C9113119'><strike id='E9C9113119'><tt id='E9C9113119'><pre id='E9C9113119'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-27 19:02:30 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：9
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Gene therapy’s promise and the high cost of hope
                                
                            
          Next article：  
                                      
                                          BioMarin wins approval for gene therapy to treat hemophilia A
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles